Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Titel:
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Auteur:
Gauler, T.C. Besse, B. Mauguen, A. Meric, J.B. Gounant, V. Fischer, B. Overbeck, T.R. Krissel, H. Laurent, D. Tiainen, M. Commo, F. Soria, J.C. Eberhardt, W.E.E.